Comparable survival between HIV+ and HIV− non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation

Díez-Martín, José Luís; Balsalobre, Pascual; Re, Alessandro; Michieli, Mariagrazia; Ribera, Josep‐Marǐa; Canals, Carmen; Conde, Eulogio; Rosselet, Anne; Gabriel, Ian; Varela, Rosario; Allione, Bernardino; Cwynarski, Kate; Genet, Philippe; Espigado, Ildefonso; Biron, Pierre; Schmitz, Norbert; Hunter, A; Ferrant, Augustin; Guillerm, Gaëlle; Hentrich, M.; Jurado, Manuel; Fernández, Pascual; Serrano, David; Rossi, Giuseppe; Sureda, Anna

doi:10.1182/blood-2008-12-195388

Cited by 127 publications

(73 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Survival of HIV-infected patients with HL was poor before cART became available but has improved considerably since then: survival is now approaching that of HIV-negative patients. [33][34][35][36][37][38] A recent study of European HL patients diagnosed between 1995 and 1999 showed that, in HIV-negative men 15 to 44 years of age, survival at one year was 98%, 39 whereas in our study the corresponding survival was 86% (95% CI, 73%-93%).…”

Section: Discussioncontrasting

confidence: 44%

HIV-1–related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes

Bohlius

Schmidlin

Boué

et al. 2011

Blood

102

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 44%

HIV-1–related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes

Bohlius

Schmidlin

Boué

et al. 2011

Blood

102

View full text Add to dashboard Cite

show abstract

“…3,4 A recent study demonstrated an improvement in the outcome of patients with HIV-associated HL compared with their immunocompetent counterparts when treated with standard regimens. 5,6 However, a standard of care in HIV-positive individuals has not been established, because, in general, HIVpositive patients are excluded from clinical trials, and data on their outcomes are rather scant.…”

Section: Introductionmentioning

confidence: 99%

Prognostic factors for advanced‐stage human immunodeficiency virus‐associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi‐institutional retrospective study

Castillo

Bower

Brühlmann

et al. 2014

Cancer

Self Cite

View full text Add to dashboard Cite

; for the HIV-Associated Hodgkin Lymphoma in the cART Era Study Group BACKGROUND: The treatment and outcomes of patients with human immunodeficiency virus (HIV)-associated Hodgkin lymphoma (HL) continue to evolve. The International Prognostic Score (IPS) is used to predict the survival of patients with advanced-stage HL, but it has not been validated in patients with HIV infection. METHODS: This was a multi-institutional, retrospective study of 229 patients with HIV-associated, advanced-stage, classical HL who received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) plus combination antiretroviral therapy. Their clinical characteristics were presented descriptively, and multivariate analyses were performed to identify the factors that were predictive of response and prognostic of progression-free survival (PFS) and overall survival (OS). RESULTS: The overall and complete response rates to ABVD in patients with HIV-associated HL were 91% and 83%, respectively. After a median follow-up of 5 years, the 5-year PFS and OS rates were 69% and 78%, respectively. In multivariate analyses, there was a trend toward an IPS score >3 as an adverse factor for PFS (hazard ratio [HR], 1.49; P5.15) and OS (HR, 1.84; P5.06). A cluster of differentiation 4 (CD4)-positive (T-helper) cell count <200 cells/lL was associated independently with both PFS (HR, 2.60; P5.002) and OS (HR, 2.04; P5.04). The CD4-positive cell count was associated with an increased incidence of death from other causes (HR, 2.64; P5.04) but not with death from HL-related causes (HR, 1.55; P5.32). CONCLUSIONS: The current results indicate excellent response and survival rates in patients with HIV-associated, advanced-stage, classical HL who receive ABVD and

show abstract

“…A matched-pair analysis of the EBMT of 53 HIV þ patients with an equal number of HIV-patients with NHL and HL revealed no significant difference in NRM, OS or PFS in the HIV À and HIV þ groups, indicating that in the era of HAART HIV positivity need not be a contraindication to auto-SCT. 70 HIV þ patients with high-risk disease at presentation, or those with relapsing or refractory disease have also been shown to have encouraging outcomes. The group at the City of Hope Hospital performed auto-SCT on 20 such patients, 6 (30%) with BL.…”

Section: Transplantation In Bclumentioning

confidence: 99%

The role of hematopoietic SCT in adult Burkitt lymphoma

Ahmed

Sureda

Aljurf

2012

Bone Marrow Transplant

View full text Add to dashboard Cite

Comparable survival between HIV+ and HIV− non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation

Abstract: Autologous stem cell transplantation (ASCT) has been successfully used in HIV-related lymphoma (HIV-Ly

Cited by 127 publications

References 15 publications

HIV-1–related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes

HIV-1–related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes

Prognostic factors for advanced‐stage human immunodeficiency virus‐associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi‐institutional retrospective study

The role of hematopoietic SCT in adult Burkitt lymphoma

Contact Info

Product

Resources

About